So far namely, to our knowledge using PARP and WEE1 inhibitors in combination for oropharyngeal or head and neck cancer has still not been pursued, despite positive effects for other cancers, as shown and reviewed by others [36,37,48,49,50]. The gene discussed is PARP1; the disease is cancer.